EFMH
TEVA icon

E Fund Management (HK)’s Teva Pharmaceuticals TEVA Stock Holding History

E Fund Management (HK)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2K Buy
655
+191
+41% +$6.36K 0.01% 296
2026
Q1 		$14K Buy
+464
New +$14.9K 0.01% 278

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

E Fund Management (HK)'s TEVA Position: Q2 2026 in Review

E Fund Management (HK) increased its Teva Pharmaceuticals (TEVA) stake by 41% in Q2 2026, buying an estimated $6.36K and bringing the position to 655 shares worth $22.2K. The position accounts for 0.01% of the portfolio, ranked #296.

E Fund Management (HK) first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • E Fund Management (HK) held 655 shares of Teva Pharmaceuticals worth $22.2K as of Q2 2026.
  • E Fund Management (HK) bought 191 Teva Pharmaceuticals shares in Q2 2026, an estimated $6.36K.
  • Teva Pharmaceuticals made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #296 holding.
  • E Fund Management (HK) first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.